AW
ALNY icon

Avion Wealth’s Alnylam Pharmaceuticals ALNY Stock Holding History

Avion Wealth’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9K Sell
32
-16
-33% -$4.83K ﹤0.01% 619
2026
Q1 		$15K Buy
48
+15
+45% +$5.1K ﹤0.01% 386
2025
Q4 		$13K Sell
33
-4
-11% -$1.77K ﹤0.01% 420
2025
Q3 		$16K Sell
37
-1
-3% -$407 ﹤0.01% 368
2025
Q2 		$12K Buy
38
+20
+111% +$5.53K ﹤0.01% 410
2025
Q1 		$4K Hold
18
– – ﹤0.01% 566
2024
Q4 		$4K Sell
18
-3
-14% -$789 ﹤0.01% 564
2024
Q3 		$5K Buy
21
+6
+40% +$1.56K ﹤0.01% 506
2024
Q2 		$3K Buy
15
+9
+150% +$1.42K ﹤0.01% 538
2024
Q1 		$1K Hold
6
– – ﹤0.01% 829
2023
Q4 		$1K Buy
6
+1
+20% +$170 ﹤0.01% 664
2023
Q3 		$0 Buy
5
+2
+67% +$382 ﹤0.01% 788
2023
Q2 		$0 Buy
+3
New +$595 ﹤0.01% 698

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Avion Wealth's ALNY Position: Q2 2026 in Review

Avion Wealth reduced its Alnylam Pharmaceuticals (ALNY) stake by 33% in Q2 2026, selling an estimated $4.83K and leaving 32 shares worth $9K. The position accounts for ﹤0.01% of the portfolio, ranked #619.

Avion Wealth first reported a position in ALNY in Q2 2023 and has held it in 13 quarters since. The position peaked at $16K in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Avion Wealth held 32 shares of Alnylam Pharmaceuticals worth $9K as of Q2 2026.
  • Avion Wealth sold 16 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $4.83K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Avion Wealth's portfolio in Q2 2026, its #619 holding.
  • Avion Wealth first reported a position in Alnylam Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • Avion Wealth's Alnylam Pharmaceuticals position peaked at $16K in Q3 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Avion Wealth's 13F filing for Q2 2026, filed 31 Jul 2026.